632 related articles for article (PubMed ID: 11415462)
21. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
[TBL] [Abstract][Full Text] [Related]
22. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
[TBL] [Abstract][Full Text] [Related]
23. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
Croucher D; Saunders DN; Ranson M
J Biol Chem; 2006 Apr; 281(15):10206-13. PubMed ID: 16459332
[TBL] [Abstract][Full Text] [Related]
24. Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.
Jensen JK; Dolmer K; Gettins PG
J Biol Chem; 2009 Jul; 284(27):17989-97. PubMed ID: 19439404
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the calcium site in two complement-like domains from the low-density lipoprotein receptor-related protein (LRP) and comparison with a repeat from the low-density lipoprotein receptor.
Dolmer K; Huang W; Gettins PG
Biochemistry; 1998 Dec; 37(48):17016-23. PubMed ID: 9836596
[TBL] [Abstract][Full Text] [Related]
26. Sites within the 39-kDa protein important for regulating ligand binding to the low-density lipoprotein receptor-related protein.
Warshawsky I; Bu G; Schwartz AL
Biochemistry; 1995 Mar; 34(10):3404-15. PubMed ID: 7533537
[TBL] [Abstract][Full Text] [Related]
27. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.
Kounnas MZ; Henkin J; Argraves WS; Strickland DK
J Biol Chem; 1993 Oct; 268(29):21862-7. PubMed ID: 7691818
[TBL] [Abstract][Full Text] [Related]
28. High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.
Migliorini M; Li SH; Zhou A; Emal CD; Lawrence DA; Strickland DK
J Biol Chem; 2020 Jan; 295(1):212-222. PubMed ID: 31792055
[TBL] [Abstract][Full Text] [Related]
29. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
30. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.
Mikhailenko I; Considine W; Argraves KM; Loukinov D; Hyman BT; Strickland DK
J Cell Sci; 1999 Oct; 112 ( Pt 19)():3269-81. PubMed ID: 10504332
[TBL] [Abstract][Full Text] [Related]
31. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
32. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein.
Stefansson S; Muhammad S; Cheng XF; Battey FD; Strickland DK; Lawrence DA
J Biol Chem; 1998 Mar; 273(11):6358-66. PubMed ID: 9497365
[TBL] [Abstract][Full Text] [Related]
33. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
35. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
36. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
37. Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein.
Rettenberger PM; Oka K; Ellgaard L; Petersen HH; Christensen A; Martensen PM; Monard D; Etzerodt M; Chan L; Andreasen PA
J Biol Chem; 1999 Mar; 274(13):8973-80. PubMed ID: 10085143
[TBL] [Abstract][Full Text] [Related]
38. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
39. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Bu G; Maksymovitch EA; Schwartz AL
J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
[TBL] [Abstract][Full Text] [Related]
40. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
